COVID-19 Patient with Moderate Liver Injury and Acute Respiratory Distress Syndrome (ARDS)
DOI:
https://doi.org/10.11594/jk-risk.03.1.7Keywords:
COVID-19, Kerusakan hati, cidera hati, ARDS, Peradangan, sitokinAbstract
Pendahuluan: Penyakit coronavirus 2019 (COVID-19) masih berlangsung. Beberapa data menunjukkan bahwa penyakit ini menyerang berbagai organ, terutama pada kasus yang parah dan kritis. Kerusakan hati dan ARDS merupakan komplikasi yang sering terjadi pada pasien COVID-19. Tujuan penulisan makalah ini adalah untuk melaporkan dan mendiskusikan terapi pada kasus-kasus yang ditemukan oleh penulis sehingga diharapkan dapat bermanfaat secara klinis.
Ilustrasi kasus: Laki-laki 35 tahun dengan hasil swab nasofaring positif COVID-19 dengan kerusakan hati dan ARDS. Pasien mendapatkan protokol terapi standar pada saat perawatan di rumah sakit, plasma konvalesen 3 kolf dan terapi setelah perawatan di rumah sakit. Pasien telah membaik.
Diskusi: Menekan hiperaktivasi sitokin merupakan target utama dalam terapi COVID-19 agar tidak berkembang menjadi stadium yang lebih parah. Pemilihan favipiravir, colchicine, dexamethasone, UDCA, dan vitamin D adalah terapi yang menargetkan mekanisme ini.
Kesimpulan: Pasien dengan gejala berat hingga kritis berisiko mengalami kondisi yang lebih buruk bahkan kematian. Mengatasi hiperaktivasi sitokin merupakan target utama terapi kasus COVID-19, sehingga pemilihan obat yang digunakan didasarkan pada mekanisme patogenesis tersebut. Selain itu, pemberian terapi suportif lainnya juga perlu diperhatikan untuk penatalaksanaan yang lebih optimal.
Downloads
References
Cai, Q et al. 2020. COVID-19: Abnormal Liver Function Test. Journal of Hepatology : 73, pp 566-574
Li, J and Fan JG. 2020. Characteristics and Mechanisms of Liver Injury in 2019 Coronavirus Disease. Journal of Clinical and Translational Hepatology : 8, pp 13-17
Cha, MH , Reguero M, and Sandhu DS. 2020. Gastrointestinal and Hepatic Manifestation of COVID-19 : A Comprehensive Review. World J Gastroenterol : 26 (19), pp : 2323 – 2332
Zahedi, M., et al. 2020. Liver Function in Novel Coronavirus Disease (COVID-19): A Systematic Review and Meta-Analysis. https://doi.org/10.1101/2020.05.20.20108357
Woreta, TA., and Alqahtani, SA. 2014. Elevation of Abnormal Liver Test. Med Clin N Am 98. pp 1-16
Cao, P et al. 2021. Elevated Serum Ferritin Level Effectively Discriminates Severity Illness and Liver Injury of Coronavirus Disease 2019 Pneumonia. Biomarkers: 26 (3), pp 207 – 212
Kumar, MP., et al. 2020. Coronavirus Disease (COVID-19) and The Liver : A Comprehensive Systematic Review and Meta-analysis. Hepatology International : 14(5), 711-722
Zhang, Y., Zheng, L., Liu, L., Zhao, M., Xiao, J., and Zhao, Q. 2020. Liver Impairment in COVID-19 Patients : A Retrospective Analysis of 115 Cases From a Single Center in Wuhan City, China. Liver International :40 (9), pp 2095-2103.
Cepelak, I., Dodig, S., and Vucenik, I. 2020. Hyperferritinemia and COVID-19?. RAD CASA Medical Sciences. pp. 18-25
Hoiyo, S., et al. 2020. How COVID-19 Induced Cytokine Storm With High Mortality. Inflammation and Regeneration, 40 : 37
Abdullah, HM., et al. 2020. Severe Refractory COVID-19 Patients Responding to Convalescent Plasma: A Case Series. Annals of Medicine and Surgery : 56, 125-127
Fatoni, AZ., Rakhmatullah, R. 2021. Acute Respiratory Distress Syndrome (ARDS) in Pneumonia COVID-19. Journal of Anesthesia and Pain : 2(1), pp 11-24
Ni, Y., et al. 2021. Immunological Perspective on the Pathogenesis, Diagnosis, Prevention, and Treatment of COVID-19. Molecular Biomedicine : 2(1)
Ye, Q., Wang, B., and Mao, J. 2020. The Pathogenesis and Treatment of The 'Cytokine Storm' in COVID-19. Journal of Infection, pp : 607-613
Tang C., Wang ., Lv H., Guan Z., and Gu J. 2020. Caution Against Corticosteroid-based COVID-19 Treatment. Lancet : 395(10239):1759 –60
Patel, SK., et al. 2020. Dexamethasone : A Boon for Critically Ill COVID-19 Patients?. Travel Medicine and Infectious Diseases : 37
Horby, P., et al. 2020. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N. Engl. J. Med : 384 (8), pp 693-704
Sharum, K., et al. 2020. Dexamethasin to Combat Cytokine Storm in COVID-19 : Clinical Trials and Preliminary Evidance. International Journal of Surgery : 82 , 179 – 181
Gomez, GM, et al. 2020. Colchicine: A Potential Therapeutic Tool Against COVID-19. Experience of 5 Patients. Rheumatol Clinic.https://doi.org/10.1016/j.reuma.2020.05.001
Reyes, AZ., et al. 2021. Anti-inflammatory Therapy for COVID-19 Infection : The Case for Colchicine. Ann Rheum Dis : 80 , pp 550 – 557
Joshi, S., et al. 2021. Role of Favipiravir in The Treatment of COVID-19. International Journal of Infectious Diseases : 102 , 501 – 508
Agrawal, U., Raju, R., and Udwadia, ZF. 2020. Favipiravir : A New and Emerging Antiviral Option in COVID-19. ScienceDirect : 75, pp 370-376
Olry, A., Meunier, L., Delire, B., Larrey, D., Horsmans, Y., and Louet, HL. 2020. Drug-Induced Liver Injury and COVID-19 Infection : The Rules Remain The Same. Drug Saf : 43 (7), pp 615-617
Bethesda. 2017. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. United States : National Institute of Diabetes and Digestive and Kidney Diseases
Burhan, E., et al. 2020.Guidelines for the Management of COVID-19 Edition 3. Jakarta :Indonesian Association of Pulmonary Doctors (PDPI) Indonesian Association of Cardiovascular Specialists (PERKI) Indonesian Association of Internal Medicine Specialists (PAPDI) Indonesian Association of Anesthesiologists and Intensive Therapy (PERDATIN) Indonesian Association of Pediatricians (IDAI)
Carubbi, F., et al. 2021. Ferritin is Associated with The Severity of Lung Involvement but Not With Worse Prognosis in Patients With COVID-19 : Data from Two Italian COVID-19 Units.Sci Rep : 11 (4863)
Bertolini, A., et al. 2020. Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis. Hepatology : 72 (5), 1864-1872
Mucha, SR., et al. 2020. Coagulopathy in COVID-19 : Manifestation and Management. Cleveland Clinic of Medicine : 87(8) 461–8
Ali, N. 2020. Role of Vitamin D in Preventing of COVID-19 Infection, Progression, and Severity. Journal of Infection and Public Health : 13, 1373 – 1380
Raharusuna, P., Priambada, S., Budiarti, C., Agung, E., Budi, C. 2020. Patterns of COVID-19 Mortality and Vitamin D: An Indonesian Study. SSRN J : http://dx.doi.org/10.2139/ssrn.3585561
Mexitalia, M., Susilawati, M., Pratiwi, R., and Susanto, JC. 2020. Vitamin D and Sun Exposure to Prevent COVID-19: Facts or Myths?. Med Hosp : 7 (1A) , pp 320 – 328
Orantes, LDC., et al. 2021. Oral anticoagulation with rivaroxaban as thromboprophylaxis in patients recovered from COVID-19 pneumonia in Veracruz, Mexico. Journal of Anesthesia and Critical Care : 13 (1), pp 12-15
The European Society for Cardiology. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. https://www.escardio.org/Education/COVID-19-and-Cardiology/ESCCOVID-19-Guidance . (Last updated: 10 June 2020)
National Institute in Health. Coronavirus Disease 2019 (COVID-19) Treatment Guideline. https://www.covid19treatmentguidelines.nih.gov/antithrombotic-therapy/. (Last update : 11 February 2021)
Abdulrab, S., Al-Maweri, S., and Halboub, E. 2020.Ursodeoxycholic acid as a therapeutic candidate to alleviate and/or prevent COVID-19-associated cytokine storm. Medical Hypotheses. https://doi.org/10.1016/j.mehy.2020.109897
Subramanian, S., Iles, T., Ikramuddin, S., and Steer, CJ. 2020. Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients. Vaccines (Basel) : 8 (2), 320
Chen, L., Xiong, J., Boo, L., and Shi, Y. 2020. Convalescent Plasma as A Potential Therapy for COVID-19.Lancet: 20, https://doi.org/10.1016/S1473-3099(20)30132-8
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges and earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
